EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Emerging roles of metal solute carriers in cancer mechanisms and treatment

Nancy N Jong, Mark J McKeage

Biopharmaceutics & Drug Disposition · 2014-11 · 35 (8) · 450-462

DOI: 10.1002/bdd.1903 ↗

At a glance

Übersichtsarbeit in Biopharmaceutics & Drug Disposition, published online on 2014-09-05. Written by Nancy N Jong and 1 co-authors. Institution: Department of Pharmacology and Clinical Pharmacology and Auckland Cancer Society Research Centre, University of Auckland, Auckland, 1142, New Zealand. Major MEDLINE topics: Models, Biological. Cited 21 times so far (Crossref); 33 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The literature concerning the roles of metal transporting solute carriers in the development and progression of human cancer, and in the delivery of metal‐containing anticancer drugs, chemical carcinogens and imaging agents, is reviewed. A range of different solute carrier families, including members from the SLC2A , SLC11A, SLC22A, SLC25A, SLC30A, SLC31A, SLC39A, SLC40A, SLC47A and SLCO1B families, and various metal substrates, including arsenic, copper, gadolinium, iron, platinum and zinc, have been implicated in these cancer‐related transport processes. For example, the transport of platinum‐based anticancer drugs has been reported to be influenced by the expression and activities of OCT1‐3 ( SLC22A1‐3), OCTN1/2 (SLC22A4/5 ), CTR1/2 ( SLC31A1/2 ) and MATE1/2 ( SLC47A1/2 ) solute carriers. As another example, solute carriers mediate control over the availability of endogenous metal ions, such as copper, iron and zinc, may have key roles in regulating tumour angiogenesis, cell proliferation, epithelial‐to‐mesenchymal transition and aberrant MAPK and STAT‐3 signal transduction in cancer. In conclusion, emerging mechanisms involving metal transporting solute carriers are being defined and seem likely to make major contributions to cancer development and progression, and to the delivery of anticancer and tumour imaging agents. Copyright © 2014 John Wiley & Sons, Ltd.

Subjects

MeSH terms (MEDLINE)

Models, BiologicalAnimalsAnion Transport ProteinsAntineoplastic AgentsBiological TransportCation Transport ProteinsGlucose Transport Proteins, FacilitativeHumansMetalsMitochondrial ADP, ATP TranslocasesNeoplasm ProteinsNeoplasmsTissue Distribution

Author keywords

SLC transportersangiogenesiscancercancer chemotherapymetal transport and uptake

Substances

Anion Transport ProteinsAntineoplastic AgentsCation Transport ProteinsGlucose Transport Proteins, FacilitativeMetalsNeoplasm ProteinsMitochondrial ADP, ATP Translocases

Authors and institutions

  • Department of Pharmacology and Clinical Pharmacology and Auckland Cancer Society Research Centre, University of Auckland, Auckland, 1142, New Zealand.

Cite

APA

Jong, N. N., & McKeage, M. J. (2014). Emerging roles of metal solute carriers in cancer mechanisms and treatment. Biopharmaceutics & Drug Disposition, 35(8), 450-462. https://doi.org/10.1002/bdd.1903

Vancouver

Jong NN, McKeage MJ. Emerging roles of metal solute carriers in cancer mechanisms and treatment. Biopharmaceutics & Drug Disposition. 2014;35(8):450-462. doi:10.1002/bdd.1903

BibTeX
@article{Jong2014,
  author = {Jong, Nancy N and McKeage, Mark J},
  title = {Emerging roles of metal solute carriers in cancer mechanisms and treatment},
  journal = {Biopharmaceutics & Drug Disposition},
  year = {2014},
  volume = {35},
  number = {8},
  pages = {450--462},
  doi = {10.1002/bdd.1903}
}
Start for free →